CRISPR Gene Editing 360

CRISPR Gene Editing 360

Friday, June 08  

8:30 - 11:00 AM

The CRISPR Gene Editing technology has been heralded as the scientific discovery of our time. This revolutionary new technique can reprogram cells in humans, plants and insects – practically any piece of DNA on the planet.

Clinical research trials are already underway in humans. Soon, gene editing will affect nearly every form of medical treatment available. With the enormous potential of this technology to impact almost every sector of society come unanswered questions:

Is it ethical to change the genetic makeup of a person to alleviate a disease state?
Who gets to own a technology capable of altering a human chromosome?
Will insurance companies pay for therapies that use gene editing?

In the past few years, the largest investment in biotechnology has been made in the gene editing field – billions of dollars are at stake!

This symposium will bring together a group of nationally and internationally recognized experts to explore the scientific, medical, ethical, legal and financial aspects of gene editing – from a 360-degree perspective. An opening presentation by each of the speakers will be followed by a panel discussion and questions and answers.


Debra J. H. Mathews
Ph.D., MA
Assistant Director for Science Programs,
Johns Hopkins Berman Institute of Bioethics Associate Professor Department of Pediatrics, Johns Hopkins University School of Medicine

Eric Kmiec

Gene Editing Institute Christiana Care’s Helen F. Graham Cancer Center & Research Institute

Bob Oakes
Delaware Office
Fish and Richardson

Edmund Pezalla
M.D.,MPH, Ph.D.
Founder and CEO
Enlightenment Bioconsult


Mark Greene

Research Director
Center for Science, Ethics & Public Policy University of Delaware




Christiana Hospital, Ogletown-Stanton Road, Newark, DE, USA